TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
21.48
+0.07 (+0.33%)
At close: 4:01PM EST

21.44 -0.04 (-0.19%)
After hours: 4:44PM EST

Stock chart is not supported by your current browser
Previous Close21.41
Open21.31
Bid21.33 x 1200
Ask21.47 x 200
Day's Range20.88 - 21.61
52 Week Range10.85 - 37.94
Volume17,032,749
Avg. Volume26,690,893
Market Cap21.824B
Beta0.68
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2017-11-27
1y Target EstN/A
Trade prices are not sourced from all markets
  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist11 hours ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Dailyyesterday

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • InvestorPlaceyesterday

    Strong UnitedHealth Group Inc Earnings Keep Rally Going

    It’s exceedingly difficult to find something to dislike about UnitedHealth Group Inc (NYSE:UNH) stock. In a healthcare sector filled with minefields over the past few years, UnitedHealth stock has tripled over the past four years. Valuation might seem a slight concern, but UNH stock isn’t that expensive on an earnings basis, nor is its balance sheet particularly levered.

  • What’s Teva Pharmaceutical’s Research and Development Strategy?
    Market Realistyesterday

    What’s Teva Pharmaceutical’s Research and Development Strategy?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.

  • Teva's Trisenox Gets FDA Approval as First-Line Treatment
    Zacksyesterday

    Teva's Trisenox Gets FDA Approval as First-Line Treatment

    Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.

  • How Teva Pharmaceutical Plans to Improve Financial Profile
    Market Realistyesterday

    How Teva Pharmaceutical Plans to Improve Financial Profile

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As we saw in the previous part of this series, Teva Pharmaceutical Industries (TEVA) is determined to pay down a considerable amount of its debt totaling $32 billion over the next few years. The company aims to achieve financial stability through improvement in operating profits and stable cash flow generation over the next few years.

  • How Teva Pharmaceutical Plans to Optimize Global Generics
    Market Realistyesterday

    How Teva Pharmaceutical Plans to Optimize Global Generics

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?

  • How Teva Pharmaceutical Is Realigning Organizational Structure
    Market Realist2 days ago

    How Teva Pharmaceutical Is Realigning Organizational Structure

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? On December 14, 2017, Teva Pharmaceutical Industries (TEVA) announced its restructuring plan to cut costs by ~$3 billion over the next two years. It expects to witness a major turnaround of its business with the implementation of this plan.

  • What Are Insys Therapeutics’ Top Priorities?
    Market Realist2 days ago

    What Are Insys Therapeutics’ Top Priorities?

    Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.

  • Teva Pharmaceutical Focusing on Per Product Operating Profits
    Market Realist2 days ago

    Teva Pharmaceutical Focusing on Per Product Operating Profits

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has been focused on maximizing its revenues through its market-leading generics portfolio. The company, however, has been facing stiff competition in the generics market from Mylan (MYL), Gilead Sciences (GILD), and Pfizer (PFE), which has resulted in price erosion in the generics market.

  • Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?
    Market Realist2 days ago

    Can Teva’s Debt Repayment Plan Deleverage Its Balance Sheet?

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? Teva Pharmaceutical Industries (TEVA) has a debt of $34 billion on its balance sheet. The company is focused on reducing its net debt obligations to optimum levels over the coming years.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    These three small biotech stocks saw huge jumps. Can their momentum continue?

  • What’s behind Insys Therapeutics’ Legal Tangles?
    Market Realist5 days ago

    What’s behind Insys Therapeutics’ Legal Tangles?

    Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

  • Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes
    Bloomberg5 days ago

    Teva's Debt Cut to Junk by Moody's, Adding to Drugmaker's Woes

    Teva Pharmaceutical Industries Ltd.’s credit rating was cut into junk territory by Moody’s Investors Service, adding to the company’s woes as revenue from its bestselling drug drops and it sells assets ...

  • A Look at Insys Therapeutics’ Financial Performance
    Market Realist5 days ago

    A Look at Insys Therapeutics’ Financial Performance

    Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.

  • MarketWatch5 days ago

    Teva credit rating downgraded to junk status at Moody's

    Teva Pharmaceuticals Industries Ltd.'s credit rating was downgraded two notches into junk status at Moody's Investors Service, which cited concerns over the drug maker's sizable debt. The rating agency ...

  • What Analysts Recommend for Insys Therapeutics and Peers
    Market Realist5 days ago

    What Analysts Recommend for Insys Therapeutics and Peers

    What to Expect from Insys Therapeutics in 2018Company overview

  • Moody's5 days ago

    Teva Pharmaceutical Finance Netherlands II BV -- Moody's downgrades Teva to Ba2; outlook stable

    Rating Action: Moody's downgrades Teva to Ba2; outlook stable. Global Credit Research- 12 Jan 2018. New York, January 12, 2018-- Moody's Investors Service downgraded the senior unsecured ratings of Teva ...

  • Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
    Market Realist5 days ago

    Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? As part of its recent restructuring plan, Teva Pharmaceutical Industries (TEVA) announced a $3 billion restructuring plan in December 2017. As part of its cost-saving initiative, the company plans to shut down some of its manufacturing facilities and cut its employee base.

  • The Key Challenges Teva Pharmaceutical Is Facing
    Market Realist5 days ago

    The Key Challenges Teva Pharmaceutical Is Facing

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) announced a restructuring plan to recuperate sales. Its stock has had a bull run since the announcement, rising 44.5% since the company’s weak earnings results for fiscal 3Q17 on November 2, 2017.

  • Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
    Market Realist5 days ago

    Why Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?Teva stock upgraded by Mizuho Securities

  • What Does Teva’s Recently Announced Restructuring Plan Entail?
    Market Realist6 days ago

    What Does Teva’s Recently Announced Restructuring Plan Entail?

    On December 14, 2017, Teva (TEVA) stock gained more than 10% on the back of the announcement of a comprehensive restructuring plan and additional measures to improve the company’s operational and financial performance. On December 14, 2017, the Generic Drugs ETF (GNRX) rose by approximately 1.0%. Teva Pharmaceuticals has a debt of $32 billion, which needs to be serviced in an organized manner to strengthen the company’s financials and bring down leverage.

  • Elagolix May Advance the Treatment Paradigm in Women’s Health
    Market Realist6 days ago

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application (or NDA) for its investigational drug Elagolix, which is used for managing endometriosis-related pain, had been granted priority review by the FDA. AbbVie has developed Elagolix in collaboration with Neurocrine Biosciences (NBIX). AbbVie expects this oral gonadotropin-releasing hormone (or GnRH) antagonist to be approved by its Prescription Drug User Fee Act (or PDUFA) date in 2Q18.

  • The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
    Motley Fool6 days ago

    The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017

    Teva threw everything but the kitchen sink at its shareholders last year, but the future is beginning to look brighter.

  • General Electric among IQ 100 laggards
    CNBC Videos5 days ago

    General Electric among IQ 100 laggards

    The CNBC IQ 100 index beating the broader market over one year up 24%. Today's leaders include Seagate, Motorola and Teva Pharma. The laggards Dexcom, Mattel and GE.